Diabetes News

Tirzepatide significantly reduced HF outcomes and symptoms for patients with HF and preserved ejection fraction and obesity, according to the top-line results of the phase 3 SUMMIT clinical trial.

Individuals with type 2 diabetes who received semaglutide had lower probability for medical care related to tobacco dependence compared with other antidiabetes medications, the results of a study in the Annals of Internal Medicine showed.

Results showed patients with insulin-dependent diabetes may have increased risk for postoperative complications and hospital readmissions after total shoulder arthroplasty vs. patients with diabetes and without insulin dependence.

NEW ORLEANS — In part three of a three-part video exclusive series, Jonathan D. Leffert, MD, talks with Kimber Simmons, MD, MS, about how providers should discuss treatments for people with early-stage type 1 diabetes.

NEW ORLEANS — In part two of a three-part video exclusive series, Jonathan D. Leffert, MD, talks with Rifka C. Schulman-Rosenbaum, MD, FACE, FACP, about the steps providers should take when a patient screens positive for type 1 diabetes.

NEW ORLEANS — In part one of a three-part video exclusive series, Jonathan D. Leffert, MD, talks with Anna Casu, MD, about the preclinical stages of type 1 diabetes and who should be screened for the disease.

The FDA granted breakthrough device designation for an endoscopic procedure that resurfaces the duodenum lining to allow for weight maintenance after discontinuation of a GLP-1 receptor agonist, according to an industry press release.

The presence of thyroid autoantibodies may be detected as early as age 10 months for children, and those positive for both thyroid peroxidase and thyroglobulin autoantibodies have a higher risk for thyroid disease, according to study data.

Use of a DPP-IV inhibitor, SGLT2 inhibitor or GLP-1 receptor agonist does not increase risk for diabetic macular edema among adults with type 2 diabetes and diabetic retinopathy, according to study data.

The FDA is warning providers and patients that dosing errors with compounded injectable semaglutide may be leading to adverse events, according to a press release.